2nd Quarter - Amendment
VIROPHARMA INCORPORATED for VIROPHARMA INCORPORATED
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 20, 2012 | $140,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Oct 26, 2012 | $120,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
340B Drug Pricing Program, accelerated approval, antibiotic incentives, bioequivalence of locally acting drugs, drug safety/supply chain integrity, drug shortages, essential health benefits, Medicaid coverage, Medicare coverage and reimbursement, and Orphan Drug Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN EDWARD GREISSING | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.